Amylyx Pharmaceuticals (AMLX) Q2 FY26 earnings call

Amylyx Pharmaceuticals is nearing a critical inflection point with the imminent Phase 3 LUCIDITY top-line data readout for avexitide in post-bariatric hypoglycemia (PBH), expected in late August or early September. The company is actively preparing for a potential NDA submission and commercial launch in 2027, while also advancing its broader pipeline and maintaining a cash runway into 2028. The focus remains on execution to bring the first FDA-approved therapy to PBH patients.